All In Biotech

Drug Trial Radar · NCT00701129

An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme®-Naive, CRIM(-) Patients With Infantile-onset Pompe Disease

Last checked: Nov 20, 2026Latest source record: May 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

4

Actual

Start

Oct 2009

Primary completion

Mar 2013

Study completion Mar 2013

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jun 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy, clinical benefits and safety of a prophylactic immunomodulatory regimen given prior to first treatment with alglucosidase alfa (Myozyme®) in patients with infantile-onset Pompe disease. The objectives were to assess the efficacy of a prophylactic immunomodulatory regimen given prior to first treatment with alglucosidase alfa, as assessed by anti-recombinant human acid alpha-glucosidase (anti-rhGAA) antibody titers, and antibodies that inhibit the activity and/or uptake of alglucosidase alfa; to evaluate the clinical benefit as measured by overall survival, ventilator-free survival, left ventricular mass index (LVMI), gross motor function and development, disability index and the incidence of adverse events (AEs), serious adverse events (SAEs), and clinical laboratory abnormalities.

Conditions

  • Pompe Disease
  • Glycogen Storage Disease Type II

Interventions

  • Alglucosidase AlfaBiological

    Administered as IV infusion.

  • MethotrexateDrug

    Administered subcutaneously.

  • RituximabDrug

    Administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Number of Patients With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G (IgG) Antibody at End of StudyTime frame: Baseline, End of Study (up to Week 79 or early termination)
  2. Number of Patients With Recombinant Human Acid Alfa-glucosidase (rhGAA) Inhibitory Antibody at End of StudyTime frame: End of study (up to Week 79)
  3. Number of Patients Who Survived at End of StudyTime frame: Baseline up to End of study (Week 79)
  4. Number of Patients With Normal/Abnormal Left Ventricular Mass (LVM) Z-Score and LVM Index at End of StudyTime frame: End of study (up to Week 79 or early termination)
  5. Number of Patients With Ventilator Use at End of StudyTime frame: End of study (up to Week 79 or early termination)
  6. Gross Motor Disability Assessed by Gross Motor Function Measure-88 (GMFM-88) at End of StudyTime frame: End of study (up to Week 79 or early termination)
  7. Motor Development Status Assessed by Alberta Infantile Motor Scale (AIMS) at End of StudyTime frame: End of study (up to Week 79 or early termination)
  8. Disability Index Assessed by the Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) at End of StudyTime frame: End of study (up to Week 79 or early termination)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kosair Children's Hospital

    Louisville, Kentucky

  • Duke University Medical Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.